PERSPECTA

News from every angle

← Back to headlines

Novo Nordisk Partners with Vivtex for Oral Weight-Loss Drug Development

Novo Nordisk has entered a collaboration with Vivtex, investing up to $2.1 billion, to develop new oral weight-loss medications.

25 Feb, 13:53 — 25 Feb, 13:53
PostShare

Sources

Showing 1 of 2 sources
seeking-alphaMixed165d ago

Novo bets up to $2.1B in Vivtex deal for oral obesity and diabetes drugs

Read full article →

Coverage Timeline

First report: berlingske · 25 Feb, 13:38Full coverage: 2 · 15mWindow: 15m
Left-leaningCenterRight-leaning
berlingske25 Feb, 13:38First to report

Novo indgår samarbejde om udvikling af vægttabsmedicin i pilleform

seeking-alpha25 Feb, 13:53Latest update

Novo bets up to $2.1B in Vivtex deal for oral obesity and diabetes drugs

Related Stories

Stock Funds Decline in July Amid AI Volatility

25m ago

Multiple Companies Release Latest Quarterly Earnings Reports

30m ago

MTN Nigeria Confirms 25GB Data Reward, Warns Against Fake Links

31m ago

Renovated Apartment for Sale in Starigrad Paklenica with Sea View

35m ago